Psychiatric Department
Toulouse, 31059, France
NCT Number: NCT00465608
Problem and Objectives: There is currently no pharmacological treatment for curing post traumatic stress disorder (PTSD). The investigators will test whether propranolol when given immediately after trauma evocation is able to decrease the strength of the traumatic memory, and by extension, the severity of PTSD symptoms associated with that memory.
Hypotheses:
1. The subjects will show a significant pre/post decrease in PTSD symptoms. 2. Those gains will be maintained at follow-up.
Study Design: Open pharmacological trial.
Method: On the first visit (V1), the subjects will describe their traumatic experience in writing and will receive the propranolol. A script describing this experience will be constructed to be used in the subsequent encounters to elicit the trauma memory. A week later (V2), before receiving the propranolol, subjects will be asked to read aloud their trauma script while imagining it as vividly as possible for 10 minutes. This weekly treatment will be repeated 6 times (from V1 to V6). A total of 6 doses of propranolol will be given. A self-report measure will be used to monitor improvement in PTSD symptomatology on the following visits: V1, V4, V6, V7 and V8 (3 month follow-up).
Statistical Analyses: A repeated measure ANOVA (pre-test, post-test, and 3-month follow-up) using the PTSD symptom score will be conducted.. Three t-tests will be performed to examine simple effects. The alpha level will be set at p = .05 (two-tailed). Fisher's exact test will be used to examine whether Ss still meet the diagnostic criteria for PTSD at the end of the study.
Clinical Implications: If this treatment is effective, a randomized controlled trial will be launched. This treatment has the potential to become the first pharmacological treatment designed to cure PTSD.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Toulouse, 31059, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cardiological consultation will be obtained as necessary.
propranolol by mouth (per os)
Other names: betablocker
Time frame: 3 months
Time frame: 3 months
University Hospital, Toulouse
Other
Reduction of the Traumatic Memory by Reconsolidation Blockade: A Pilot Study
Acronym: Reductrauma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00431847
Anxiety Disorders, Autonomic Nervous System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT00739765
Anxiety Disorders, Mental Disorders
New York, United States
View Trial DetailsNCT06680193
Mental Disorders, Post-traumatic Stress Disorder
Denton, Texas, United States
View Trial DetailsNCT01517711
Combat Disorders, Mental Disorders
Cincinnati, Ohio, United States
View Trial Details